Can preclinical drug development help to predict adverse events in clinical trials?

Area of Science:

• Pharmacology
• Toxicology
• Biotechnology

Background:

• Drug development faces high attrition rates due to unexpected adverse events, leading to severe health outcomes.
• Current preclinical safety tests often fail to accurately represent human physiology, missing critical toxicity signals.
• Life-threatening events like organ failure and cancer have occurred in clinical trials unexpectedly.

Purpose of the Study:

• To highlight novel technologies for improved preclinical safety assessment in drug development.
• To demonstrate the utility of advanced platforms in predicting unforeseen toxicity.
• To advocate for the integration of these technologies to enhance therapeutic safety.

Main Methods:

• Utilized high-throughput screening for early toxicity detection.
• Employed organs-on-chips to model human physiological responses.
• Incorporated microbiome-containing drug-testing platforms for complex interactions.
• Applied humanized mouse models for in vivo safety evaluations.

Main Results:

• Novel technologies successfully enabled mechanistic studies of toxicity.
• These advanced platforms demonstrated predictive capability for adverse events.
• The application of these methods identified potential safety concerns not seen in traditional testing.

Conclusions:

• Advanced preclinical safety testing technologies offer significant improvements over traditional methods.
• Integrating these novel platforms into drug development pipelines can mitigate risks associated with hazardous therapeutics.
• Adoption of these technologies promises to reduce attrition rates and enhance patient safety in clinical trials.